|
Emergent BioSolutions protects your thorax against anthrax. The company develops and produces vaccines that treat or protect against infectious diseases and bio-agents. The company supplies BioThrax (the US's only FDA-approved anthrax vaccine) primarily to the departments of Defense and Health and Human Services (HHS). Its biodefense unit is also developing a post-exposure treatment for anthrax and a preventive vaccine for botulinum toxin. For commercial markets, Emergent BioSolutions is working on therapies and vaccines for such infectious diseases as typhoid, tuberculosis, hepatitis B, and Chlamydia. Chairman and CEO Fuad El-Hibri controls half of the company.
|
| | | Contact Information | |
Address: |
2273 Research Blvd., Ste. 400
Rockville, MD 20850
| | Phone: | 301-795-1800 | | Fax: | 301-795-1899 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 178.60 M | | Revenue Growth (1 yr): | (-2.40%) | | Employees (2008): | 587 | | Employee Growth (1 yr): | 4.80% |
|
|
Key People
| | • |
Chairman and CEO:
Fuad El-Hibri
| | • |
President, COO, and Director:
Daniel J. Abdun-Nabi
| | • |
SVP Finance and Administration, CFO, and Treasurer:
R. Don Elsey
|
|
|
